Compare Costco Wholesale Corporation (COST) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs Novo Nordisk A/S — how do they compare? Costco Wholesale Corporation trades at $944.56 (market cap $420.05B), while Novo Nordisk A/S trades at $38.41 (market cap $165.31B). The key difference: Costco Wholesale Corporation is far larger — about 2.5× Novo Nordisk A/S's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Costco Wholesale Corporation for 132 Days and Novo Nordisk A/S for 116 Days on average.
| COST | NVO | |
|---|---|---|
Market Cap | $420.05B | $165.31B |
Volume | 2,087,565 | 11,432,838 |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $63.98 |
52-Week Low | $849.63 | $35.29 |
Typical Hold Time | 132 Days | 116 Days |
Enterprise Value | $407.33B | $179.56B |
Dividend Yield | 0.62% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Costco (COST) trades at $942.25, up 0.7% on the day, showing strong operational momentum with a 28.4% ROE and 11.3% March sales growth. The stock is near its 52-week high, supported by bullish moving averages, though RSI levels indicate potential overbought conditions. Recent membership fee hikes and robust cash flow generation underscore its resilient business model.
Outlook remains positive given analyst consensus and a $1,090 price target, but elevated P/E of 45.66 poses valuation risk. Key catalysts include sustained membership growth and expansion, while risks involve competitive pressures and macroeconomic sensitivity.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
